Merck's Q3 sales reached $16.7 billion, a 4% YoY increase, beating the $16.5 billion consensus estimate. Merck reported a decline of 11% in sales of Gardasil to $2.31 billion, a vaccine that ...

Wells Fargo analyst Mohit Bansal lowered the firm’s price target on Merck (MRK) to $110 from $125 and keeps an Equal Weight rating on the shares. Merck’s Gardasil expectation reset is a step ...

(1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue ...

A key panel of U.S. health advisers voted in favor of lowering the age recommendation for vaccines made by Pfizer Inc. and Merck & Co. that protect against pneumococcal disease, clearing a path ...

Merck will face an important patent cliff by the end of the decade. The company has a plan to move beyond it. Competition from a new therapy shouldn't derail Merck's prospects. Even when we zoom ...

With these approvals, KEYTRUDA is now authorized for 30 indications in the EU, including five in gynecologic cancers, Merck said in a statement. RAHWAY: Merck, also known as MSD outside the US and ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

Merck’s acquisition of Modifi Biosciences will give it access to preclinical cancer drug candidates that target DNA repair processes. Modifi Biosciences, a spin out of Yale University founded in 2021, ...

Merck, for instance, was cleared by U.S. regulators in June to begin selling Capvaxive. That shot protects against 21 types of the bacteria that cause pneumococcal disease, including eight not covered ...

The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the ...